In a new study published in Clinical Pharmacology & Therapeutics, SCOHIA PHARMA, Inc., report the results of a phase 1 clinical trial for SCO-240, an orally available somatostatin receptor type 5 (SSTR5) antagonist.
Article Title
Oral SSTR5 antagonist SCO-240 for growth hormone stimulation: A phase 1 single-dose study in healthy individuals
Link to the article (external website): https://doi.org/10.1002/cpt.3212
Somatostatin inhibits endocrine and exocrine secretion in various tissues by acting on five somatostatin receptor subtypes (SSTR1–5). The effects of SSTR5 antagonism in humans remain unelucidated to date. We have evaluated the effects of SCO-240, an oral SSTR5 antagonist, in an ascending single oral dose trial in healthy individuals. SCO-240 was found to be safe and well-tolerated at all tested doses (1–160 mg/man/day). Oral SCO-240 was readily absorbed, with systemic exposure increasing in a dose-dependent manner, supporting a once-daily dose regimen. Of note, a single oral dose of SCO-240 induced robust growth hormone (GH) secretion without altering the levels of other pituitary hormones. This study is the first to demonstrate that SSTR5 antagonism stimulates GH secretion in humans. The robust effects of SCO-240 on GH secretion suggest that it may offer an oral treatment option for GH-related disorders.
SCOHIA is actively seeking a partner worldwide for further development and commercialization of SCO-240.
Effects of a single oral dose of SCO-240 in healthy individuals
Values are presented as the mean ± SD (n = 14 and 6 for the placebo and SCO-240 groups, respectively). #P < 0.05 and *P < 0.05 vs. placebo as tested using the Williams’ test and the Shirley-Williams test, respectively.
SCOHIA PHARMA, Inc. is a drug discovery company focused on the discovery and development of new treatments addressing unmet medical needs with a high level of expertise in endocrine, cardiovascular, renal, and metabolic systems. For more information about SCOHIA PHARMA, Inc., please visit https://www.scohia.com/eng/